Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2024-08-09 00:00:00 ET · period of report 2024-08-08 · accession 0002001011-24-000067 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-08-09 | 2024-08-08 | LGND | Davis Todd C | CEO, Dir | P - Purchase | $97.39 | +2,500 | 123.0K | +2% | +$243.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-08-08 | P | A | 2,500 | $97.39 | 123,010 | D | — | — |